Oric Pharmaceuticals
Kyle Edgar has extensive experience in scientific research, currently serving as a Staff Scientist and previously as a Sr. Principal Scientist at ORIC Pharmaceuticals Inc. since December 2019. Prior to this role, Kyle held the position of Principal Scientific Researcher at Genentech for 14 years, from November 2005 to November 2019. Additional experience includes a Specialist role at Chiron Corporation for a brief period in 2005 and various positions such as Research Associate and Research Technician at Exelixis from May 1998 to July 2005. Kyle Edgar earned a Bachelor of Science degree in Biochemistry and Molecular Cell Biology from the University of Arizona, completing studies there from 1994 to 1998.
Oric Pharmaceuticals
ORIC Pharmaceuticals is a privately held, clinical-stage oncology company focused on making cancer treatments more effective by addressing mechanisms of resistance. ORIC's lead asset, ORIC-101, is a potent and selective small-molecule antagonist of the glucocorticoid receptor. ORIC's pipeline targets other undisclosed mechanisms of oncology therapy resistance. ORIC's scientific founders are Drs. Charles Sawyers, MD, and Scott Lowe, PhD, who have strong records of discovering innovative treatments and targets in cancer. The company has assembled strong leadership and scientific teams and a board with extensive experience in drug development and financing. ORIC is funded by leading biotechnology investors, including The Column Group, Topspin Partners, OrbiMed Advisors, EcoR1 Capital, Fidelity Management & Research Company, Trinitas Capital, Foresite Capital, Taiho Ventures, Memorial Sloan Kettering, Kravis Investment Partners, NS Investment and City Hill Ventures. ORIC is headquartered in South San Francisco, California.